EVLO - Evelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczema

Evelo Biosciences (NASDAQ:EVLO) said the first patient was dosed in a phase 2 trial of EDP1815 to treat patients with mild, moderate, and severe atopic dermatitis, also known as eczema. Results from the phase 2 study, dubbed EDP1815-207, are expected in 1H 2023. "Our previously released Phase 1b data, together with the positive results we recently released from our Phase 2 trial in mild and moderate psoriasis, demonstrate that EDP1815 has the potential to be a safe, effective, well tolerated, oral, inflammation resolving therapy,” said Evelo's (EVLO) Chief Development Officer Jonathan Zung.

For further details see:

Evelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczema